Scholar Hub Community:
https://yscholarhub.yonsei.ac.kr/handle/2021.sw.yonsei/4410
2024-03-29T00:06:03Z
2024-03-29T00:06:03Z
Profiling of conditionally reprogrammed cell lines for in vitro chemotherapy response prediction of pancreatic cancer
Hee Seung Lee
EunYoung Kim
JINYOUNG LEE
seongjoon park
ho kyoung hwang
CHANHEE PARK
조세영
Chang Moo Kang
Seung-Mo Hong
Huapyong Kang
JUNG HYUN JO
INRAE CHO
Moon Jae Chung
JEONG YOUP PARK
Seung Woo Park
SI YOUNG SONG
Jung Min Han
SANGWOO KIM
Seungmin Bang
https://yscholarhub.yonsei.ac.kr/handle/2021.sw.yonsei/5256
2024-03-08T14:29:23Z
2021-03-01T00:00:00Z
Title: Profiling of conditionally reprogrammed cell lines for in vitro chemotherapy response prediction of pancreatic cancer
Authors: Hee Seung Lee; EunYoung Kim; JINYOUNG LEE; seongjoon park; ho kyoung hwang; CHANHEE PARK; 조세영; Chang Moo Kang; Seung-Mo Hong; Huapyong Kang; JUNG HYUN JO; INRAE CHO; Moon Jae Chung; JEONG YOUP PARK; Seung Woo Park; SI YOUNG SONG; Jung Min Han; SANGWOO KIM; Seungmin Bang
Abstract: Background: The establishment of patient-derived models for pancreatic ductal adenocarcinoma (PDAC) using conventional methods has been fraught with low success rate, mainly because of the small number of tumour cells and dense fibrotic stroma. Here, we sought to establish patient-derived model of PDAC and perform genetic analysis with responses to anticancer drug by using the conditionally reprogrammed cell (CRC) methodology. Methods: We performed in vitro and in vivo tumourigenicity assays and analysed histological characteristics by immunostaining. We investigated genetic profiles including mutation patterns and copy number variations using targeted deep sequencing and copy-number analyses. We assessed the responses of cultured CRCs to the available clinical anticancer drugs based on patient responsiveness. Findings: We established a total of 28 CRCs from patients. Of the 28 samples, 27 showed KRAS mutations in codon 12/13 or codon 61. We found that somatic mutations were shared in the primary-CRC pairs and shared mutations included key oncogenic mutations such as KRAS (9 pairs), TP53 (8 pairs), and SMAD4 (3 pairs). Overall, CRCs preserved the genetic characteristics of primary tumours with high concordance, with additional confirmation of low-AF NPM1 mutation in CRC (35 shared mutations out of 36 total, concordance rate=97.2%). CRCs of the responder group were more sensitive to anticancer agents than those of the non-responder group (P < 0.001). Interpretation: These results show that a pancreatic cancer cell line model can be efficiently established using the CRC methodology, to better support a personalized therapeutic approach for pancreatic cancer patients. Funding: 2014R1A1A1006272, HI19C0642-060019, 2019R1A2C2008050, 2020R1A2C209958611, and 2020M3E5E204028211 © 2021 The Authors
2021-03-01T00:00:00Z